NCT04670601已完成1 期
Bioequivalence Study of Flurbiprofen 8.75 mg Lozenge vs. the Reference Product Strepfen 8.75 mg Lozenge in Healthy Volunteers
Aziende Chimiche Riunite Angelini Francesco S.p.A1 个研究点 分布在 1 个国家目标入组 24 人开始时间: 2018年6月19日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 24
- 试验地点
- 1
- 主要终点
- Maximum Plasma Concentration
研究概览
简要总结
The present study has been designed to compare flurbiprofen pharmacokinetic profile after administration of flurbiprofen 8.75 mg lozenges, marketed by ACRAF, S.p.A., Italy (test product), and the marketed Strepfen 8.75 mg honey and lemon lozenges reference product. (Reckitt Benckiser Portugal SA).
详细描述
This is a single dose, open-label, randomised, 2-way cross-over bioequivalence study aimed to compare the bioavailability and the plasma pharmacokinetic profile of flurbiprofen after single dose administration of test and reference formulations.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Informed consent: signed written informed consent before inclusion in the study.
- •Sex and Age: males and females, 18-55 years old inclusive.
- •Habits: non smokers.
- •Body Mass Index (BMI): 18.5-30 kg/m2 inclusive.
- •Vital signs: systolic blood pressure (SBP) 100-139 mmHg, diastolic blood pressure (DBP) 50-89 mmHg, heart rate (HR) 50-90 bpm, measured after 5 min at rest in the sitting position.
- •Full comprehension: ability to comprehend the full nature and purpose of the study, including possible risks and side effects; ability to co-operate with the investigator and to comply with the requirements of the entire study.
- •Contraception and fertility (women only): females of child-bearing potential must be using at least one of the following reliable methods of contraception:
- •Hormonal oral, implantable, transdermal, or injectable contraceptives for at least 2 months before the screening visit
- •A non-hormonal intrauterine device [IUD] or female condom with spermicide or contraceptive sponge with spermicide or diaphragm with spermicide or cervical cap with spermicide for at least 2 months before the screening visit
- •A male sexual partner who agrees to use a male condom with spermicide
- •A sterile sexual partner Women of non-child-bearing potential or in post-menopausal status for at least 1 year will be admitted.
- •For all women, pregnancy test result must be negative at screening and day -1.
排除标准
- •Electrocardiogram (12-lead ECG in supine position): clinically significant abnormalities.
- •Physical findings: clinically significant abnormal physical findings which could interfere with the objectives of the study; subjects with dry mouth conditions or with any other diseases/problems of the mouth which the investigator considers may affect the outcome of the study.
- •Laboratory analyses: clinically significant abnormal laboratory values indicative of physical illness.
- •Allergy: ascertained or presumptive hypersensitivity to the active principle and/or formulations' ingredients; history of anaphylaxis to drugs or allergic reactions in general, which the investigator considers may affect the outcome of the study.
- •Diseases: significant history of renal, hepatic, gastrointestinal, cardiovascular, respiratory, skin, haematological, endocrine or neurological diseases that may interfere with the aim of the study.
- •Medications: medications, including over the counter (OTC) medications and herbal remedies, in particular flurbiprofen, for 2 weeks before the start of the study. Hormonal contraceptives for females will be allowed
- •Investigative drug studies: participation in the evaluation of any investigational product for 3 months before this study. The 3-month interval is calculated as the time between the first calendar day of the month that follows the last visit of the previous study and the first day of the present study
- •Blood donation: blood donations for 3 months before this study
- •Drug, alcohol, caffeine, tobacco: history of drug, alcohol [>1 drink/day for females and >2 drinks/day for males, defined according to the USDA Dietary Guidelines 2015-2020 (9)], or caffeine abuse (>5 cups coffee/tea/day); smokers
- •Drug test: positive result at the drug test at screening or day-1
- •Alcohol test: positive alcohol breath test at day -1
- •Diet: abnormal diets (<1600 or >3500 kcal/day) or substantial changes in eating habits in the 4 weeks before this study; vegetarians
- •Pregnancy (women only): positive or missing pregnancy test at screening or day -1, pregnant or lactating women
研究组 & 干预措施
Strepfen 8.75 mg
Active Comparator
Strepfen 8.75 mg lemon and honey lozenge
干预措施: Flurbiprofen Reference 8.75 MG (Drug)
Flurbiprofen 8.75 mg
Experimental
Flurbiprofen 8.75 mg lemon and honey flavour lozenge
干预措施: Flurbiprofen Test 8.75 MG (Drug)
结局指标
主要结局
Maximum Plasma Concentration
时间窗: pre-dose (0), 10, 20, 30, 40, 50 minutes and 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 16 and 24 hours post-dose
to evaluate the rate (Cmax) of absorption of flurbiprofen in plasma after single dose administration
Area under the plasma concentration-time curve 0-t
时间窗: pre-dose (0), 10, 20, 30, 40, 50 minutes and 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 16 and 24 hours post-dose
to evaluate the extent of absorption of flurbiprofen in plasma after single dose administration
次要结局
- tlag(pre-dose (0), 10, 20, 30, 40, 50 minutes and 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 16 and 24 hours post-dose)
- Treatment-Emergent Advers Events(through the two week study period)
- Time to achieve Cmax(pre-dose (0), 10, 20, 30, 40, 50 minutes and 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 16 and 24 hours post-dose)
- Relative bioavailability of flurbiprofen in plasma(pre-dose (0), 10, 20, 30, 40, 50 minutes and 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 16 and 24 hours post-dose)
- Palatability(2 times through the two week study period)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Bioequivalence Study of FLURBIPROFEN 100 mg FAMOTIDINE 20 mg MULTI-LAYER TABLET in Healthy Subjects Under Fasting ConditionsHealthyNCT01910090Pharmaceutical Research Unit, Jordan36
已完成
3 期
A Study of Flurbiprofen 8.75 mg Lozenge in Patients With PharyngitisPharyngitisNCT01048866Reckitt Benckiser LLC198
已完成
1 期
Study to Test the Blood to See if a New Medicine is Likely to Provide Pain Relief Similar to a Product Already Sold in StoresPainNCT01555476McNeil AB32
已完成
3 期
A Study of Flurbiprofen 8.75 mg Lozenge in Patient With PharyngitisPharyngitisNCT01049334Reckitt Benckiser LLC204
已完成
不适用
Bioequivalency Study of Buprenorphine Hydrochloride 8 mg Tablet Under Fasted ConditionsOpioid-Related DisordersNCT00992095Roxane Laboratories48